Feed Top Reports Pricing

⌘K

00:15:05·519d

SECFiling

SEC Form EFFECT filed by Axonics Inc.

AXNX· Axonics Inc.

Health Care

Original source

Companies

AXNX
Axonics Inc.
Health Care

Recent analyst ratings

Jan 9UpdateWolfe Research-
Jul 19UpdateRobert W. Baird$69.00
Jul 13UpdateKeyBanc Capital Markets$70.00
May 23UpdateCL King$75.00
Apr 14UpdateMizuho$75.00
Mar 24UpdateNeedham$71.00

Related

PR262d
RxSight, Inc. Appoints Raymond W. Cohen to Its Board of Directors
SEC514d
SEC Form 15-12G filed by Axonics Inc.
SEC524d
SEC Form 25-NSE filed by Axonics Inc.
INSIDER524d
Director Kiernan Jane E returned $1,410,131 worth of shares to the company (19,861 units at $71.00), closing all direct ownership in the company (SEC Form 4)
INSIDER524d
EVP, Chief Mktg/Strtgy Officer Woock John returned $5,495,613 worth of shares to the company (77,403 units at $71.00), closing all direct ownership in the company (SEC Form 4)
INSIDER524d
Director Snyderman Nancy Lynn Md returned $1,061,024 worth of shares to the company (14,944 units at $71.00), closing all direct ownership in the company (SEC Form 4)
INSIDER524d
Chief Operating Officer Sama Rinda returned $5,996,802 worth of shares to the company (84,462 units at $71.00), closing all direct ownership in the company (SEC Form 4)
INSIDER524d
Chief Medical Officer Noblett Karen returned $2,444,388 worth of shares to the company (34,428 units at $71.00), closing all direct ownership in the company (SEC Form 4)

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022